TTR and amyloidosis: Inotersen was the first ASO therapy evaluated in the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a pivotal phase 3 study involving 172 patients with variant transthyretin amyloidosis and polyneuropathy (ATTRv-PN) [20].